Avantor (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, reported financial results for the first quarter ended March 31, 2026.
The company posted net sales of $1,581.4 million, remaining flat compared to the first quarter of 2025, though organic sales saw a contraction of 4.1% as the industry continues to navigate a complex post-pandemic demand environment.
The company's profitability metrics highlighted a focus on operational efficiency.
Avantor reported GAAP net income of $43.3 million, or $0.06 per diluted share.
On an adjusted basis, net income was $114 million, with adjusted EPS coming in at $0.17.
Adjusted EBITDA for the quarter reached $219.4 million, representing a margin of 13.9%.
Cash flow generation remained positive, with operating cash flow at $58.7 million and free cash flow of $25.2 million for the quarter.
Meanwhile, Avantor continues to manage its balance sheet actively, reporting adjusted net leverage of 3.3x, as it prioritizes financial flexibility and strategic reinvestment into its proprietary bioprocessing capabilities.